Kazia Therapeutics features in multiple leading Australian publications

Highlights

  • Kazia Therapeutics (ASX: KZA) has recently appeared across multiple leading Australian financial publications and guest speaker at a Brisbane investor event.
  • Media mentions include small-cap publication, Stockhead, nabtrade and investment newsletter, the Switzer Report
  • Kazia CEO James Garner also presented at the Wholesale Investor Emergence event providing an update on Kazia’s lead programs and trials.

Kazia Therapeutics (ASX: KZA) has recently appeared across multiple leading Australian financial publications as well as presenting at the recent Wholesale Investor Emergence event.

CEO James Garner featured in small-cap publication, Stockhead, in regards to a bid to form an integrated approach for new options for cancer patients following Bill Shorten’s $2.3 billion cancer funding pledge.

Kazia has also been featured by financial journalist James Dunn as a leading ASX cancer stock to watch in both nabtrade and investment newsletter, the Switzer Report

Kazia CEO James Garner also presented at the Wholesale Investor Emergence event in Brisbane, detailing Kazia’s expected multiple data read-outs from its international human trials during calendar 2019 and an update on Kazia’s lead program, GDC-0084 to target glioblastoma.

 

About Kazia Therapeutics Limited (ASX: KZA)

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.

Register Interest